Browse by author
Lookup NU author(s): Emeritus Professor Herbie Newell, Gordon Taylor, Professor Hilary Calvert
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
Etoposide phosphate is a water-soluble prodrug of etoposide. A phase I and pharmacokinetic study has been performed over the dose range 25-110 mg/m(2)/day for 5 days (etoposide equivalent doses). The maximum tolerated dose (MTD) was 110 mg/m(2)/day for 5 days every 3 weeks and the dose-limiting toxicity was neutropenia. Other toxicities were mild, with the exception of 2 patients who displayed significant hypersensitivity reactions. The etoposide phosphate:etoposide area under the plasma concentration versus time curve (AUC) ratio was < 1% and the pharmacokinetic parameters for etoposide were within previously reported ranges. Pharmacodynamic analyses demonstrated that etoposide AUC and baseline white blood cell count were significant determinants of leucopenia (model r(2) = 0.51).
Author(s): Millward, M. J., Newell, D. R., Mummaneni, V., Igwemezie, L. N., Balmanno, K., Charlton, C. J., Gumbrell, L., Lind, M. J., Chapman, F., Proctor, M., Simmonds, D., Cantwell, B. M. J., Taylor, G. A., McDaniel, C., Winograd, B., Kaul, S., Barbaiya, R. H., Calvert, A. H.
Publication type: Article
Publication status: Published
Journal: European Journal of Cancer
Year: 1995
Volume: 31A
Issue: 13-14
Pages: 2409-2411
Print publication date: 01/12/1995
ISSN (print): 0959-8049
ISSN (electronic): 1879-0852
URL: http://www.ejcancer.info/article/0959-8049(95)00331-2/pdf
